346 related articles for article (PubMed ID: 31298573)
1. Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.
Failing JJ; Dudek OA; Marin Acevedo JA; Chirila RM; Dong H; Markovic SN; Dronca RS
Future Oncol; 2019 Aug; 15(22):2645-2656. PubMed ID: 31298573
[TBL] [Abstract][Full Text] [Related]
2. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
Chen K; Ye H; Lu XJ; Sun B; Liu Q
Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
[TBL] [Abstract][Full Text] [Related]
3. Pseudoprogression and hyperprogression after checkpoint blockade.
Wang Q; Gao J; Wu X
Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
[TBL] [Abstract][Full Text] [Related]
4. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Chang X; Lu X; Guo J; Teng GJ
Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
Kato S; Goodman A; Walavalkar V; Barkauskas DA; Sharabi A; Kurzrock R
Clin Cancer Res; 2017 Aug; 23(15):4242-4250. PubMed ID: 28351930
[No Abstract] [Full Text] [Related]
6. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.
Kang DH; Chung C; Sun P; Lee DH; Lee SI; Park D; Koh JS; Kim Y; Yi HS; Lee JE
Cancer Immunol Immunother; 2022 Mar; 71(3):579-588. PubMed ID: 34278517
[TBL] [Abstract][Full Text] [Related]
7. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.
Iivanainen S; Koivunen JP
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952311
[TBL] [Abstract][Full Text] [Related]
8. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy Toxicity.
Mantia CM; Buchbinder EI
Hematol Oncol Clin North Am; 2019 Apr; 33(2):275-290. PubMed ID: 30833000
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors.
Hui E
J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
12. Predicting immunotherapy response through genomics.
Cormedi MCV; Van Allen EM; Colli LM
Curr Opin Genet Dev; 2021 Feb; 66():1-9. PubMed ID: 33307238
[TBL] [Abstract][Full Text] [Related]
13. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
14. Biomarkers associated with checkpoint inhibitors.
Manson G; Norwood J; Marabelle A; Kohrt H; Houot R
Ann Oncol; 2016 Jul; 27(7):1199-206. PubMed ID: 27122549
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for immunotherapy in urological cancers.
Gust KM; Resch I; D'Andrea D
Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
18. Immunological and clinical implications of immune checkpoint blockade in human cancer.
Kim HD; Park SH
Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
[TBL] [Abstract][Full Text] [Related]
19. Clinical Challenges of Immune Checkpoint Inhibitors.
de Miguel M; Calvo E
Cancer Cell; 2020 Sep; 38(3):326-333. PubMed ID: 32750319
[TBL] [Abstract][Full Text] [Related]
20. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.
Ji Z; Peng Z; Gong J; Zhang X; Li J; Lu M; Lu Z; Shen L
BMC Cancer; 2019 Jul; 19(1):705. PubMed ID: 31315610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]